We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Tobacco Troubles Really Char Staples ETFs' Safety?
Read MoreHide Full Article
On July 28, the U.S. Food and Drug Administration (FDA) proposed to reduce nicotine levels in cigarettes to non-addictive or minimally addictive levels, due to its perilous effects on health. Since, FDA’s regulation is aimed at the addictive nature of cigarettes, the latest restriction could lower cigarette consumption and the profitability of tobacco companies.
In any case, governments around the world have been proactive in applying restrictive enforcements on tobacco companies. For example, the FDA made it compulsory for all tobacco makers to seek marketing approval for any tobacco product introduced after February 15, 2007. Moreover, the European Union and the FDA have proposed a ban on menthol in accordance with the Tobacco Control Act.
Following the proposal in late July, stocks of cigarette makers including Altria Group MO , British American Tobacco Plc (BTI - Free Report) , Philip Morris International Inc. (PM - Free Report) and Vector Group Ltd. (VGR - Free Report) fell. However, Philip Morris shares were less hurt in the lot. Most of the stocks were in the red in the last five days (as of August 3, 2017) with MO, BTI, PM and VGR sliding about 11.4%, 6.7%, 3.1% and 6.8%, respectively.
In fact, the three ETFs have about 17-20% of their exposure targeted at the tobacco industry. On the other hand, Altria has considerable exposure to FSTA, iShares Edge MSCI USA Quality Factor ETF (QUAL - Free Report) ,XLP, VDC and iShares U.S. Consumer Goods ETF (IYK - Free Report) . These funds put about 5-6.5% of their assets in Altria (read: Time to Cash in on Cola Earnings with These ETFs?).
Vector Group has an exposure of about 1.5-3.5% to PowerShares High Yield Equity Dividend Achievers Portfolio ETF (PEY - Free Report) and WisdomTree SmallCap Dividend Fund (DES - Free Report) .
BTI is invested about 3.5% to 4.3% in ETFs like BLDRS Europe Select ADR Index Fund and BLDRS Developed Markets 100 ADR Index Fund .
Are Staples ETFs Really in Trouble Over the Long Run?
Most of the above-mentioned ETFs lost in the last five days (as of August 4, 2017). Normally, staple ETFs are known for safety due to their non-cyclical business pattern. However, if tobacco companies continue to get hurt like this, consumer staples’ ETFs may see some troubles (read: Tough Time Ahead for Grocery Stocks and ETFs?).
Investors should note that these tobacco stocks offer decent levels of dividend too with Altria and Phillip Morris offering 3.72% and 3.63% yields (as of August 3, 2017). So, investors’ quest for dividend will also likely get burnt in tobacco woes.
But there is a bright side as well. Research house Cowen “does not expect regulatory changes to put tobacco company earnings at risk until at least 2019” as the FDA process is likely to be slow. The FDA is likely to be “considering a delay in implementing new rules for reduced-risk products like e-cigarettes.”
As per Cowen, companies like Philip Morris and Turning Point Brands will actually benefit from the FDA’s move as these are well positioned to boost their e-cigarette businesses. However, not all players are shielded, so, over the long term, the impact is likely to be mixed.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Tobacco Troubles Really Char Staples ETFs' Safety?
On July 28, the U.S. Food and Drug Administration (FDA) proposed to reduce nicotine levels in cigarettes to non-addictive or minimally addictive levels, due to its perilous effects on health. Since, FDA’s regulation is aimed at the addictive nature of cigarettes, the latest restriction could lower cigarette consumption and the profitability of tobacco companies.
In any case, governments around the world have been proactive in applying restrictive enforcements on tobacco companies. For example, the FDA made it compulsory for all tobacco makers to seek marketing approval for any tobacco product introduced after February 15, 2007. Moreover, the European Union and the FDA have proposed a ban on menthol in accordance with the Tobacco Control Act.
Following the proposal in late July, stocks of cigarette makers including Altria Group MO , British American Tobacco Plc (BTI - Free Report) , Philip Morris International Inc. (PM - Free Report) and Vector Group Ltd. (VGR - Free Report) fell. However, Philip Morris shares were less hurt in the lot. Most of the stocks were in the red in the last five days (as of August 3, 2017) with MO, BTI, PM and VGR sliding about 11.4%, 6.7%, 3.1% and 6.8%, respectively.
Tobacco’s ETF Exposure
Two tobacco companies – Altria and Philip Morris – has huge exposure to consumer staples ETFs. Consumer Staples Select Sector SPDR Fund (XLP - Free Report) , Fidelity MSCI Consumer Staples Index ETF (FSTA - Free Report) and Vanguard Consumer Staples ETF (VDC - Free Report) invest about 8-10% of their holdings in Philip Morris (read: ETFs in Focus After Phillip Morris's Downbeat Q2 Results).
In fact, the three ETFs have about 17-20% of their exposure targeted at the tobacco industry. On the other hand, Altria has considerable exposure to FSTA, iShares Edge MSCI USA Quality Factor ETF (QUAL - Free Report) ,XLP, VDC and iShares U.S. Consumer Goods ETF (IYK - Free Report) . These funds put about 5-6.5% of their assets in Altria (read: Time to Cash in on Cola Earnings with These ETFs?).
Vector Group has an exposure of about 1.5-3.5% to PowerShares High Yield Equity Dividend Achievers Portfolio ETF (PEY - Free Report) and WisdomTree SmallCap Dividend Fund (DES - Free Report) .
BTI is invested about 3.5% to 4.3% in ETFs like BLDRS Europe Select ADR Index Fund and BLDRS Developed Markets 100 ADR Index Fund .
Are Staples ETFs Really in Trouble Over the Long Run?
Most of the above-mentioned ETFs lost in the last five days (as of August 4, 2017). Normally, staple ETFs are known for safety due to their non-cyclical business pattern. However, if tobacco companies continue to get hurt like this, consumer staples’ ETFs may see some troubles (read: Tough Time Ahead for Grocery Stocks and ETFs?).
Investors should note that these tobacco stocks offer decent levels of dividend too with Altria and Phillip Morris offering 3.72% and 3.63% yields (as of August 3, 2017). So, investors’ quest for dividend will also likely get burnt in tobacco woes.
But there is a bright side as well. Research house Cowen “does not expect regulatory changes to put tobacco company earnings at risk until at least 2019” as the FDA process is likely to be slow. The FDA is likely to be “considering a delay in implementing new rules for reduced-risk products like e-cigarettes.”
As per Cowen, companies like Philip Morris and Turning Point Brands will actually benefit from the FDA’s move as these are well positioned to boost their e-cigarette businesses. However, not all players are shielded, so, over the long term, the impact is likely to be mixed.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>